Clinical Trial Update: BIBF 1120 for Recurrent High-Grade Gliomas [Phase 2]

View source ↗

Summary

Phase 2 trial update on BIBF 1120 (nintedanib) for recurrent high-grade gliomas, with the study status now completed and results posted in 2014. The trial asses…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Astrocytoma
• Anaplastic Oligoastrocytoma
• Anaplastic Oligodendroglioma
• Glioblastoma
• Gliosarcoma

Drugs mentioned

• BIBF 1120 (nintedanib)

Snippet

Sponsor: Patrick Y. Wen, MD | Conditions: Glioblastoma, Gliosarcoma | Phase 2 | Status: COMPLETED | Results posted: 2014-08-18